D
David P. Schenkein
Researcher at Agios Pharmaceuticals
Publications - 133
Citations - 16321
David P. Schenkein is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Bortezomib & Proteasome inhibitor. The author has an hindex of 48, co-authored 132 publications receiving 15667 citations. Previous affiliations of David P. Schenkein include University of Pennsylvania & Wesleyan University.
Papers
More filters
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,D. Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San-Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,William S. Dalton,Anthony Boral,Dixie Lee Esseltine,Jane B. Porter,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.
Journal ArticleDOI
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Sundar Jagannath,Bart Barlogie,James R. Berenson,David S. Siegel,D. Irwin,Paul G. Richardson,Ruben Niesvizky,Raymond Alexanian,Steven Limentani,Melissa Alsina,Julian Adams,Michael Kauffman,Dixie Lee Esseltine,David P. Schenkein,Kenneth C. Anderson +14 more
TL;DR: Bortezomib alone or in combination with dexamethasone demonstrated therapeutic activity in patients with multiple myeloma who relapsed after frontline therapy.
Journal ArticleDOI
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang,Jeremy Travins,Byron DeLaBarre,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Stefanie Schalm,Erica Hansen,Kimberly Straley,Andrew Kernytsky,Wei Liu,Camelia Gliser,Hua Yang,Stefan Gross,Erin Artin,Véronique Saada,Elena Mylonas,Elena Mylonas,Elena Mylonas,Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Janeta Popovici-Muller,Jeffrey O. Saunders,Francesco G. Salituro,Shunqi Yan,Stuart Murray,Wentao Wei,Yi Gao,Lenny Dang,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Stéphane de Botton,Stéphane de Botton,Stéphane de Botton,Katharine E. Yen +38 more
TL;DR: Evidence is provided that inhibitors targeting mutant IDH2/R140Q could have potential applications as a differentiation therapy for cancer, and a small molecule, AGI-6780, that potently and selectively inhibits the tumor-associated mutant IDh2/ R140Q is developed.
Journal ArticleDOI
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Stefan Gross,Rob A. Cairns,Mark D. Minden,Edward M. Driggers,Mark A. Bittinger,Hyun Gyung Jang,Masato Sasaki,Shengfang Jin,David P. Schenkein,Shinsan M. Su,Lenny Dang,Valeria Fantin,Tak Mak +12 more
TL;DR: IDH1/2 mutations confer an enzymatic gain of function that dramatically increases 2-HG in AML, providing an explanation for the heterozygous acquisition of these mutations during tumorigenesis.